{"product_id":"amgen-bcg-matrix","title":"Amgen Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where Amgen’s portfolio really sits—market leader, cash cow, dog, or a risky question mark? This snapshot teases the shifts in market share and growth across biologics and newer pipeline plays, but the full BCG Matrix maps every product into its quadrant with numbers that matter. Buy the complete report for quadrant-level placements, data-backed recommendations, and ready-to-use Word and Excel files that make strategy and capital allocation obvious. Get it now and stop guessing—plan with clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepatha (PCSK9 inhibitor)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRepatha leads a growing CV category as guidelines and payers in 2024 push lower LDL targets, driving broader access. PCSK9 inhibitors lower LDL by roughly 50–60% and trials like FOURIER showed ~15% RRR in major CV events, with real‑world data sustaining prescriber confidence. Continued education and access work are needed, but current uptake and outcomes momentum suggest durable dominance; hold market share now to compound benefits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTezspire (severe asthma)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFast traction in the biologics severe asthma segment with broad label covering multiple phenotypes including eosinophil-low patients; NAVIGATOR showed ~56% reduction in annualized exacerbation rate. Differentiation on exacerbation reduction is resonating with pulmonologists. Access and specialty distribution still need muscle, so promotion stays elevated and continued investment is warranted to cement first-call status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlincyto (ALL bispecific)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBlincyto (blinatumomab) is surging after compelling survival signals and expansion into earlier lines, including the 2021 FDA MRD-positive approval based on the BLAST trial where 78% achieved MRD negativity. Hospital adoption is rising with growing comfort in administration; its high clinical value supports premium pricing as competitors emerge. Scale medical education and infusion capacity to sustain momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvenity (osteoporosis)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvenity is positioned as the anabolic-first play in Amgen’s BCG matrix as anabolic-first strategies gain traction; romosozumab showed a 73% reduction in new vertebral fractures in pivotal data, supporting strong clinical differentiation. Sequencing with Prolia enhances patient retention and outcomes; market education is the main barrier but adoption shows a clear growth curve—keep the field force active to drive category leadership.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePosition: Star (high growth, high potential)\u003c\/li\u003e\n\u003cli\u003eClinical edge: 73% reduction in new vertebral fractures\u003c\/li\u003e\n\u003cli\u003eStrategy: Prolia sequencing = higher stickiness\u003c\/li\u003e\n\u003cli\u003eNeed: ongoing market education; prioritize sales force\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology biosimilars (Mvasi, Kanjinti, etc.)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen's oncology biosimilars (Mvasi, Kanjinti) — both FDA-approved in 2019 — hold high-share positions in key hospital-administered oncology molecules with sustained hospital and payer pull-through; category expansion continues as institutions standardize to biosimilars. Price compression is constant, but Amgen's scale and supply reliability matter; keep contracting sharp and service levels high to defend and grow share.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-share hospital presence\u003c\/li\u003e\n\u003cli\u003eFDA approvals: 2019\u003c\/li\u003e\n\u003cli\u003eCategory expanding as institutions standardize\u003c\/li\u003e\n\u003cli\u003eMaintain tight contracting + high service\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePCSK9s, anabolic osteoporosis and MRD therapies surge as biosimilars squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRepatha: category growth as 2024 LDL targets tighten; PCSK9s cut LDL 50–60% and FOURIER-class RCTs ~15% RRR in major CV events. Evenity: anabolic leader; romosozumab 73% reduction new vertebral fractures. Blincyto: MRD+ survival traction; BLAST 78% MRD negativity. Biosimilars: high hospital share since 2019; pricing pressure persists.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eBCG\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepatha\u003c\/td\u003e\n\u003ctd\u003eExpanding access\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003eLDL −50–60%; ~15% RRR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvenity\u003c\/td\u003e\n\u003ctd\u003eGrowing adoption\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003e73% ↓ vertebral fractures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlincyto\u003c\/td\u003e\n\u003ctd\u003eLine expansion\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003e78% MRD− (BLAST)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology biosimilars\u003c\/td\u003e\n\u003ctd\u003eHigh hospital share\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003eApproved 2019; margin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth review of Amgen's products across BCG quadrants, highlighting Stars, Cash Cows, Question Marks, Dogs, and recommended strategic moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Amgen BCG Matrix pinpointing portfolio pain points and guiding resource shifts for faster fixes\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnbrel (inflammation)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnbrel, a TNF inhibitor with a 26-year legacy since 1998, remains a large, mature franchise with entrenched rheumatology relationships and stable-to-soft volume in established markets. Margins are excellent for Amgen\/Pfizer given limited incremental promo required in this well-known class. Strategy: milk the cash cow while investing in patient retention and adherence programs to preserve unit share against biosimilar pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProlia\/Xgeva (denosumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProlia (6-month dosing) and Xgeva (monthly) benefit from deep physician familiarity, strong real-world evidence (FREEDOM: 68% vertebral fracture reduction) and high margins in osteoporosis and oncology bone protection. Combined denosumab net sales were about $6.1 billion in 2024, generating significant free cash flow despite modest growth. Recurring dosing drives predictable revenue; invest in operations to sustain adherence, distribution and supply reliability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOtezla (psoriasis\/psoriatic arthritis)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOtezla remains a cash cow for Amgen: oral convenience and broad access keep it a go-to versus biologics, supporting steady uptake in psoriasis\/psoriatic arthritis. Amgen reported Otezla net sales of $1.1 billion in 2024, reflecting mature demand and predictable scripts that drive reliable cash flow. Promo can be tight and targeted, preserving healthy contribution margins while funding next-wave immunology bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKyprolis (multiple myeloma)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKyprolis remains a cash cow for Amgen with established efficacy in combination regimens and strong trust among heme-onc prescribers. Market growth has cooled due to newer entrants, yet 2024 global revenue of about $2.0B remains solid. Limited incremental marketing spend is required; prioritize lifecycle optimization and real-world evidence to extend commercial runway.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished combos and prescriber trust\u003c\/li\u003e\n\u003cli\u003e2024 revenue ~ $2.0B\u003c\/li\u003e\n\u003cli\u003eMarket growth cooled, competitive pressure\u003c\/li\u003e\n\u003cli\u003eLow incremental spend to sustain position\u003c\/li\u003e\n\u003cli\u003eFocus on RWE and lifecycle to extend runway\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar base (Amjevita, others) in steady accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmjevita and other biosimilars deliver steady cash flows from contracted hospital and payer books that ensure reliable throughput and predictable margins.\u003c\/p\u003e\n\u003cp\u003eCategory growth remained muted in 2024, but favorable substitution economics and scale-based manufacturing know-how protected margin resilience.\u003c\/p\u003e\n\u003cp\u003eFocus on service continuity and avoid price erosion to preserve long-term profitability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady throughput from contracted channels\u003c\/li\u003e\n\u003cli\u003eMuted category growth in 2024\u003c\/li\u003e\n\u003cli\u003eFavorable substitution economics\u003c\/li\u003e\n\u003cli\u003eScale and manufacturing protect margins\u003c\/li\u003e\n\u003cli\u003ePrioritize service, avoid price wars\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin biologics and oral staples — protect retention, RWE \u0026amp; lifecycle to defend cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen cash cows: entrenched franchises with high margins, predictable dosing and stable-to-soft growth; prioritize retention, adherence, RWE and lifecycle tactics to defend share and cash flow. Denosumab, Otezla and Kyprolis drove substantial 2024 FCF while biosimilars and category maturity limit growth; focus on service continuity and targeted promo.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 net sales\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProlia\/Xgeva\u003c\/td\u003e\n\u003ctd\u003e$6.1B\u003c\/td\u003e\n\u003ctd\u003eDenosumab combined\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOtezla\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003ctd\u003eMature oral franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKyprolis\u003c\/td\u003e\n\u003ctd\u003e$2.0B\u003c\/td\u003e\n\u003ctd\u003eHeme-onc staple\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnbrel\/Amjevita\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eSteady biosimilar throughput\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eAmgen BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing here is the exact Amgen BCG Matrix report you'll receive after purchase—no watermarks, no placeholders, just the finished, presentation-ready document. It’s built for strategic clarity and immediate use: edit, print, or drop into your deck without fuss. Once purchased, the full file is delivered straight to your inbox—no surprises, no extra steps. Trust the preview: it’s the real thing, made by strategy pros for busy teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164015079801,"sku":"amgen-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/amgen-bcg-matrix.png?v=1762724285","url":"https:\/\/portersfiveforce.com\/products\/amgen-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}